Polymorphism analysis of CYP3A5 in myeloid leukemia

Oncology Reports

Volumn 9, Issue 2, 2002, Pages 327-329

  Liu, Ta Chih ^a   Lin, Sheng Fung ^a   Chen, Tyen Po ^a   Chang, Jan Gowth ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CYP3A5 gene; Myeloid leukemia; Polymorphism

Indexed keywords

CYP3A PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450; PRIMER DNA;

ACUTE DISEASE; ARTICLE; CASE CONTROL STUDY; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; PATHOLOGY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TAIWAN;

ACUTE DISEASE; CASE-CONTROL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; HUMANS; LEUKEMIA, MYELOID; LEUKEMIA, MYELOID, CHRONIC; MYELODYSPLASTIC SYNDROMES; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TAIWAN;

EID: 0036517359     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.2.327     Document Type: Article

References (24)

1. Bishop JM: The molecular genetics of cancer. Science 235: 305-311, 1987.
2. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
3. Cline MJ: The molecular basis of leukemia. N Engl J Med 330: 328-336, 1994.
4. Knudson AG: Chasing the cancer demon. Annu Rev Genet 34: 1-19,2000.
5. Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NV, Loveit BD, Nowell PC, Blair IA and Rebbeck TR: Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 95: 13176-13181, 1998. (Pubitemid 28509544)
6. Idle J: Is environmental carcinogenesis modulated by host polymorphism? Mutat Res 247: 259-266, 1991.
7. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL and Lucier GW: Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathiones-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 85: 1159-1164, 1993. (Pubitemid 23212283)
8. Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CGH, Lange BJ and Shannon KM: Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 79: 1438-1446, 1997. (Pubitemid 27143252)
9. Felix C, Hosier MR and Provisor D, et al: The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood 87: 4376-4381, 1996. (Pubitemid 26152278)
10. Wolf CR, Smith CAD, Gough AC, Moss JE, Vallis KA, Howard G, Carey FJ, Mills K, McNee W, Carmichael J and Spurr NK: Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis 13: 1035-1038, 1992.
11. Chen H, Sandler DP, Taylor JA, Shore DL, Liu E, Bloomfield CD and Bell DA: Increases risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347: 295-297, 1996. (Pubitemid 26041042)
12. Cholerton S, Daly AK and Idle JR: The role of individual human cytochromes p450 in drug metabolism and clinical response. Trends Pharmacol Sei 13: 434-439, 1992.
13. Shimada T, Yamazake H, Mimura M, Inui Y and Guengerich FP: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423, 1994. (Pubitemid 24229655)
14. Rendic S and Di Carlo FJ: Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29: 413-580, 1997. (Pubitemid 27293618)
15. Smith G, Stanley LA, Sim E, Strange RC and Wolf CR: Metabolic polymorphisms and cancer susceptibility. Cancer Surv 25: 27-65, 1995.
16. Raunio H, Husgafvel-Pursianen K, Anttila S, Hietanen E, Hirvonen A and Pelkonen O: Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility. Gene 159: 113-121, 1995.
17. Sonnichsen D, Liu Q, Schuetz E, Schuetz J, Pappo A and Relling M: Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 275: 566-575, 1995. (Pubitemid 26025545)
18. Kuehl P, Zhang J and Lin Y, et al: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391, 2001.
19. Liu TC, Lin PM, Chang JG, Lee JP, Chen TP and Lin SF: Mutation analysis of PTEN/MMAC1 in acute myeloid leukemia. Am J Hematol 63: 170-175, 2000.
20. Chang JG, Chen PH, Chiou SS, Lee LS, Perng LI and Liu TC: Rapid diagnosis of β-thalassemia mutations in Chinese by naturally and amplified created restriction sites. Blood 80: 2092-2096, 1992.
21. Chang JG, Chiou SS, Perng LI, Chen TC, Liu TC, Lee LS, Chen PH and Tang TK: Molecular characterization of glucose 6-phosphate dehydrogenase (G6PD) deficiency by naturally and amplification created restriction sites-five mutations account for most G6PD deficiency cases in Taiwan. Blood 80: 1079-1082, 1992.
22. Estabrook W: The remarkable P450s: a historical overview of these versatile hemoprotein catalysts. FASEB J 10: 202-204, 1996.
23. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K and Fraumeni JF Jr: The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta 1471: C1-C10, 2001. (Pubitemid 32146551)
24. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ and Malkowicz SB: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90: 1225-1229, 1998. (Pubitemid 28407089)